Anika Therapeutics, Inc. Form DEFA14A April 23, 2014

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed by the R Filed by a Par Check the app	ty other than the Registran	ıt[]	
	•	Preliminary Proxy Statement	
		Confidential, for Use of the Commission Only (as permitted by Rule	
[ ]			
	Definitive Additional Materials		
		Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12	
		IKA THERAPEUTICS, INC.	
	(Name of I	Registrant as Specified In Its Charter)	
	(Name of Person(s) Fil	ing Proxy Statement, if other than the Registrant)	
Payment of Fi	iling Fee (Check the appro	priate box):	
[X]	No fee required.		
[ ]	Fee computed on	table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	(1)	Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction	
	(-)	computed pursuant to Exchange Act Rule 0-11 (set forth the	
		amount on which the filing fee is calculated and state how it	
		was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
[ ]	Fee paid previously with preliminary materials.		
[ ]	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and		
	identify the filing for which the offsetting fee was paid previously. Identify the previous filing		
		by registration statement number, or the Form or Schedule and the date of its filing.	
	(1)	Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	

## Edgar Filing: Anika Therapeutics, Inc. - Form DEFA14A

(3) Filing Party:

(4) Date Filed: